Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Common-Size Income Statement
Quarterly Data

Bristol-Myers Squibb Co., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net product sales 97.31 97.07 97.25 97.45 97.01 96.39 96.62 97.08 96.86 96.72 97.45 97.52 97.27 96.75 96.92 97.77 96.44 96.02 96.14 96.50
Alliance and other revenues 2.69 2.93 2.75 2.55 2.99 3.61 3.38 2.92 3.14 3.28 2.55 2.48 2.73 3.25 3.08 2.23 3.56 3.98 3.86 3.50
Revenues 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of products sold, excludes amortization of acquired intangible assets -23.92 -22.85 -25.62 -22.63 -22.73 -20.98 -22.88 -21.21 -19.66 -19.71 -20.95 -25.66 -26.29 -23.74 -26.65 -33.97 -31.37 -29.80 -31.44 -30.81
Gross margin 76.08% 77.15% 74.38% 77.37% 77.27% 79.02% 77.12% 78.79% 80.34% 80.29% 79.05% 74.34% 73.71% 76.26% 73.35% 66.03% 68.63% 70.20% 68.56% 69.19%
Marketing, selling and administrative -18.06 -18.27 -17.23 -15.54 -19.87 -17.20 -15.03 -15.72 -19.64 -15.38 -16.08 -15.05 -24.58 -16.19 -16.07 -14.90 -21.83 -17.56 -17.15 -16.99
Research and development -21.59 -20.45 -20.11 -20.47 -22.01 -21.55 -19.53 -19.40 -21.01 -25.64 -21.17 -20.04 -33.88 -23.71 -24.90 -22.00 -26.39 -22.94 -21.12 -22.77
Acquired IPRD -5.23 -0.73 -1.41 -0.66 -0.46 -0.27 -3.37 -2.86 -0.74 -2.33 -6.78 -0.05 -103.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Amortization of acquired intangible assets -19.85 -20.57 -20.11 -19.90 -20.54 -21.55 -20.33 -20.75 -20.17 -21.90 -21.76 -22.69 -22.82 -23.63 -23.59 -21.17 -13.37 -0.42 -0.38 -0.41
Operating income (loss) 11.35% 17.13% 15.53% 20.79% 14.40% 18.44% 18.86% 20.05% 18.78% 15.04% 13.25% 16.51% -110.92% 12.73% 8.80% 7.97% 7.05% 29.28% 29.91% 29.02%
Other income (expense), net 3.23 2.35 1.03 3.64 1.90 1.25 -2.39 -5.57 -3.28 3.52 0.02 6.34 16.50 8.68 7.27 -10.79 -8.67 -6.83 -1.59 4.41
Earnings (loss) before income taxes 14.59% 19.49% 16.56% 24.43% 16.30% 19.69% 16.47% 14.48% 15.50% 18.56% 13.27% 22.85% -94.43% 21.41% 16.06% -2.82% -1.62% 22.46% 28.31% 33.43%
Income tax (provision) benefit 0.77 -1.85 1.94 -4.44 1.46 -5.36 -4.45 -3.47 4.29 -5.20 -4.20 -4.52 3.83 -3.60 -16.85 -4.29 -11.72 0.28 -5.37 -4.46
Net earnings (loss) 15.35% 17.64% 18.50% 20.00% 17.75% 14.33% 12.02% 11.01% 19.79% 13.35% 9.07% 18.32% -90.59% 17.82% -0.79% -7.11% -13.34% 22.74% 22.94% 28.97%
Noncontrolling interest 0.00 -0.05 -0.04 -0.04 -0.03 -0.02 -0.07 -0.04 0.00 -0.05 -0.05 -0.07 0.00 -0.06 -0.05 -0.08 0.05 -0.22 -0.11 -0.08
Net earnings (loss) attributable to BMS 15.35% 17.58% 18.47% 19.95% 17.73% 14.32% 11.95% 10.97% 19.79% 13.30% 9.01% 18.25% -90.59% 17.76% -0.84% -7.19% -13.29% 22.52% 22.83% 28.89%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Bristol-Myers Squibb Co. operating income (loss) as a percentage of revenues increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Earnings (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Bristol-Myers Squibb Co. earnings (loss) before income taxes as a percentage of revenues increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Net earnings (loss) attributable to BMS The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS as a percentage of revenues decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.